1. Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany;
2. German Consortium for Translational Cancer Research, Heidelberg, Germany;
3. Department of Internal Medicine III, Ulm University, Ulm, Germany;
4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
5. Department of Haematology, Cambridge Institute of Medical Research, and Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom;
6. Department of Hematology and Oncology, Eberhard Karls University, Tübingen, Germany;
7. Department of Hematology and Oncology, Otto von Guericke University, Magdeburg, Germany;
8. Clinical Cooperation Unit Molecular Hematology and Oncology, German Cancer Research Center, and Department of Internal Medicine V, Ruprecht Karls University, Heidelberg, Germany;
9. Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA;
10. Leukemia Center, Human Oncology and Pathogenesis Program and Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY;
11. Immune Cell Development and Host Defense Program, Fox Chase Cancer Center, Philadelphia, PA; and
12. Heidelberg Institute for Stem Cell Technology and Experimental Medicine and Division of Stem Cells and Cancer, Experimental Hematology Group, German Cancer Research Center, Heidelberg, Germany